凯普生物：截至2025年6月30日公司应收账款期末余额为192619.90万元

Core Insights - The company, Capstone Biology, reported that as of June 30, 2025, the ending balance of accounts receivable is 1,926.20 million yuan, with a bad debt provision of 985.59 million yuan, resulting in a book value of 940.61 million yuan [1] - Accounts receivable related to unconventional testing products and medical testing services from 2020 to 2022 have an ending balance of 1,296.86 million yuan and a book value of 420.67 million yuan [1] - The government has been intensifying efforts to clear debts owed by state-owned enterprises to private companies, establishing clear responsibilities and enhancing audit supervision [1] Company Management Strategies - The company prioritizes the recovery of accounts receivable as a key management task, led by senior executives and supported by finance, business, legal, and marketing departments [1] - A focused management team is established to address accounts receivable in regions with significant balances, utilizing various methods such as data verification, client visits, correspondence collection, and legal actions [1] - The company actively communicates with relevant government departments to report on the situation and gain support for coordinating repayment responsibilities among local governments [1]